Pulmonary Sarcoidosis following Etanercept Treatment

Bhamra, Kuljeet; Stevens, Richard

doi:10.1155/2012/724013

Cited by 9 publications

(5 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that sarcoidosis may involve any organ [3] or it can be limited to the eyes only [12]. The same is true for induced sarcoidosis, which may be limited to 1 organ [4, 7, 8, 9, 10, 11]. For example, it has been reported to present very atypically and involve just the hypopharynx [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Moisseiev

Shulman

2014

Case Rep Ophthalmol

View full text Add to dashboard Cite

We report the case of a 64-year-old woman with rheumatoid arthritis and bilateral visual deterioration. The patient had been treated with certolizumab, a new tumor necrosis factor alpha (TNFα) antagonist, and her findings were consistent with bilateral uveitis, suggestive of sarcoidosis. Here, we review the literature on TNFα antagonist-induced sarcoidosis and report the first case of uveitis induced by certolizumab. Awareness of the possibility of this unique complication is important for both rheumatologists and ophthalmologists who treat patients with this new agent.

show abstract

Section: Discussionmentioning

confidence: 99%

“…TNFα-induced sarcoidosis may not demonstrate all the systemic manifestations of the disease and may involve only 1 organ. Several case reports have been published describing pulmonary [ 7 , 8 , 9 ] or cutaneous [ 10 , 11 ] sarcoidosis following treatment with TNFα antagonists.…”

Section: Discussionmentioning

confidence: 99%

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Moisseiev

Shulman

2014

Case Rep Ophthalmol

View full text Add to dashboard Cite

show abstract

“…At least 47 cases have occurred. Fortunately, the prognosis is good, with 37 of 47 patients experiencing complete resolution of the event after discontinuation [15,16]. …”

Section: Pulmonary Sarcoidosismentioning

confidence: 99%

Nonsteroidal therapy of sarcoidosis

Korsten

Mirsaeidi

Sweiss

2013

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. Recent findings Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. Summary Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

show abstract

“…Coexistence of sarcoidosis and sacroiliitis has been published in numerous case reports [ 9 ]; however the prevalence of sacroiliitis and spondyloarthritis has not been reported in sarcoidosis. Evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF- α therapy, with disease reversal after discontinuation [ 10 ]. Therefore, this study is designed to determine the prevalence of sacroiliitis and spondyloarthritis in patients diagnosed with sarcoidosis and to establish any possible correlation with the findings of the disease.…”

Section: Introductionmentioning

confidence: 99%

The Prevalence of Sacroiliitis and Spondyloarthritis in Patients with Sarcoidosis

Kobak

Sever

İnce

et al. 2014

International Journal of Rheumatology

View full text Add to dashboard Cite

Introduction. Sarcoidosis is a chronic granulomatous disease, which can involve different organs and systems. Coexistence of sarcoidosis and spondyloarthritis has been reported in numerous case reports. Purpose. To determine the prevalence of sacroiliitis and spondyloarthritis in patients previously diagnosed with sarcoidosis and to investigate any possible relation with clinical findings. Materials and Methods. Forty-two patients with sarcoidosis were enrolled in the study. Any signs and symptoms in regard to spondyloarthritis (i.e., existence of inflammatory back pain, gluteal pain, uveitis, enthesitis, dactylitis, inflammatory bowel disease, and psoriasis) were questioned in detail and biochemical tests were evaluated. Sacroiliac joint imaging and lateral heel imaging were performed in all patients. Results. Sacroiliitis was found in 6 of the 42 (14.3%) sarcoidosis patients and all of these patients were female. Common features of the disease in these six patients were inflammatory back pain as the major clinical complaint, stage 2 sacroiliitis as revealed by radiological staging, and the negativity of HLA B-27 test. These six patients with sacroiliitis were diagnosed with spondyloarthritis according to the criteria of ASAS and of ESSG. Conclusion. We found spondyloarthritis in patients with sarcoidosis at a higher percentage rate than in the general population (1–1.9%). Controlled trials involving large series of patients are required for the confirmation of the data.

show abstract

Pulmonary Sarcoidosis following Etanercept Treatment

Cited by 9 publications

References 4 publications

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Nonsteroidal therapy of sarcoidosis

The Prevalence of Sacroiliitis and Spondyloarthritis in Patients with Sarcoidosis

Contact Info

Product

Resources

About